Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Octapharma
Age
12–65
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Severe hemophilia A (FVIII:C \<= 1%)
Male subjects between 12 and 65 years of age
Body weight 25 kg to 110 kg
Previously treated with FVIII concentrate for at least 150 EDs
You may not be if
Other coagulation disorder than hemophilia A
Present or past FVIII inhibitor activity
Clareo Health | Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
